Physician profile
Anna Lincoln
NPI 1518973791
$836.27
in general payments reported to CMS, 2019-2025
14 companies · $123 in 2025
The $123 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $105 · 2021: $90.16 · 2022: $82.72 · 2023: $58.28 · 2024: $181 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $191.49 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $172.42 | 2019-2024 | |
| Pfizer INC. | $104.84 | 2019-2022 | |
| Tris Pharma INC | $73.17 | 2019-2021 | |
| Shire North American Group INC | $72.63 | 2019 | |
| Collegium Pharmaceutical, INC. | $45.48 | 2025 | Jornay Pm |
| Corium, LLC | $42.45 | 2023-2024 | Azstarys |
| Adlon Therapeutics L.P. | $29.95 | 2019-2020 | |
| Sobi, INC | $29.65 | 2020-2021 | |
| Alk-Abello, INC | $26.22 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $18.56 | 2024 | Ycanth |
| Vertical Pharmaceuticals, LLC | $14.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.47 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Lincoln listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.